嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展

Progress of chimeric antigen receptor T-cell therapy for multiple myeloma

多发性骨髓瘤(MM)是第二常见的血液系统恶性肿瘤。近年来,蛋白酶体抑制剂、免疫调节药物等新一代药物显著改善了MM患者的预后,中位生存期延长至3~6年。同时,嵌合抗原受体T细胞(CAR-T)免疫疗法在治疗复发难治MM方面取得了巨大进展,但高复发率和较短的缓解时间仍然是CAR-T治疗亟待解决的问题。需探究影响CAR-T疗效和安全性的因素,优化CAR-T治疗策略。文章对2023年第65届美国血液学会(ASH)年会报道的关于CAR-T治疗MM的前沿进展进行总结。

Multiple myeloma(MM)is the second most common hematologic malignancy.In recent years,the advent of a new generation of drugs including proteasome inhibitors and immunomodulatory drugs has significantly improved the prognosis of MM patients,extending the median survival to 3-6 years.Meanwhile,chimeric antigen receptor T-cell(CAR-T)immunotherapy has made great progress in treating relapsed/refractory MM,but the high relapse rate and short remission duration are still challenges for CAR-T therapy.Therefore,it is imperative to explore factors affecting the efficacy and safety of CAR-T therapy and optimize the treatment strategies.This article reviews the recent advances in CAR-T therapy for MM reported at the 65th American Society of Hematology(ASH)Annual Meeting in 2023.